Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NSCLC × nimotuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Nasopharyngeal Carcinoma 18 Esophageal Squamous Cell Carcinoma 11 Esophageal Neoplasms 11 Uterine Cervical Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 8 Pancreatic Neoplasms 8 Carcinoma, Non-Small-Cell Lung 8 Head and Neck Neoplasms 6 Stomach Neoplasms 3 Neoplasms 3 Recurrence 2 Pancreatic cancer, adult 2 Neoplasm Metastasis 2 Nasopharyngeal Neoplasms 2 Lung Neoplasms 2 Diffuse Intrinsic Pontine Glioma 2 Colorectal Neoplasms 2 Carcinoma 2 Adenocarcinoma 2 Uterine Cervical Dysplasia 1 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Anal Canal 1 Solid Tumors 1 Solid Tumor 1 Resectable Pancreatic Cancer 1 Penile Neoplasms 1 Pancreatic Cancer Resectable 1 Oropharyngeal Neoplasms 1 Nasopharyngeal Diseases 1 NSCLC 1

Interventions

osimertinib 11 Pemetrexed 11 Carboplatin 11 aflutinib 8 Gefitinib 8 Drug Therapy 8 Radiotherapy 6 anlotinib 5 Docetaxel 5 Cisplatin 5 pembrolizumab 4 icotinib 4 Vinorelbine 4 Radiosurgery 4 Paclitaxel 4 Gemcitabine 4 Erlotinib Hydrochloride 4 tislelizumab 3 apatinib 3 HM781-36B 3 toripalimab 2 spartalizumab 2 rezivertinib 2 dacomitinib 2 camrelizumab 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01861223 2014-02-25

Afatinib Plus Nimotuzumb for NSCLC

Samsung Medical Center

Phase 1/2 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡